Riesgo de Trombogénesis en usuarias de contraceptivos hormonales e infección por COVID-19 asociada: criterios de elegibilidad y recomendaciones

Abstract

Introduction: The risk of developing thrombogenesis in women of childbearing age is low and when associated with the use of combined hormonal contraceptives, in addition to COVID-19 infection, this risk may be increased. Objective: To identify the risk of thrombogenesis in women who use hormonal contraceptives and its association with COVID-19 infection in order to choose the risks and benefits of using hormonal contraceptives according to the eligibility criteria and their recommendations.

Methods: a non-systematic bibliographic review with descriptive methodology was carried out using scientific articles in Spanish and English published in databases such as Scielo, Pubmed and Elsevier in a period not exceeding 5 years. Results: Of 52 scientific articles, 38 were selected according to the established inclusion parameters such as Spanish and English language, information according to the topic and age. Discussion: hormonal contraception combined has been shown to be very safe, but it must be taken into account that hormonal treatments are usually associated with an increase in the development of thrombosis, especially contraceptives that have third and fourth generation progestogens in their composition. It is important to assess the risk of thromboembolic disease in patients with hormonal contraception, because COVID-19 infection predisposes to thrombus formation. Conclusions: Given the relationship between the use of hormonal contraceptives and COVID-19 infection with an increased risk of developing thrombogenesis, although it should be emphasized that this risk, although not exact, is extremely low, it is important that hormonal contraceptive treatments should be be indicated individually, evaluating the risk and benefit for each patient.